Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Dispute Resolution Strategies: FDA Clarifies Which Issues Can Be Appealed

Executive Summary

Matters ripe for appeal above review division level include denial of request for breakthrough therapy designation, revised guidance states, but general advice – such as how to conduct a clinical research program – are not appealable.

Advertisement

Related Content

KemPharm Seeks FDA Dispute Resolution Over Apadaz's Abuse Deterrence
Totality Of ‘Breakthrough’ Evidence Guides FDA Designation Decisions

Topics

Advertisement
UsernamePublicRestriction

Register